2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Ser/Thr Kinase
  5. Ser/Thr Kinase Inhibitor

Ser/Thr Kinase Inhibitor

Ser/Thr Kinase Inhibitors (8):

Cat. No. Product Name Effect Purity
  • HY-103020
    BAY-1816032
    		Inhibitor 99.05%
    BAY-1816032 is a potent and oral available BUB1 (budding uninhibited by benzimidazoles 1) kinase inhibitor with an IC50 of 7 nM.
  • HY-161111
    KVS0001
    		Inhibitor 99.14%
    KVS0001 is a potent inhibitor of SMG1 and nonsense mediated decay (NMD) that has anti-tumor activity.
  • HY-104001
    BAY-524
    		Inhibitor 99.48%
    BAY-524 is a potent Bub1 kinase inhibitor. BAY-524 inhibits the recombinant catalytic domain of human Bub1 with an IC50 of 450 nM. BAY-524 can be used for the research of anti-cancer in combination with other agents.
  • HY-147655
    CQ211
    		Inhibitor 99.58%
    CQ211 is a potent and selective RIOK2 inhibitor with a Kd of 6.1 nM. CQ211 exhibits potent proliferation inhibition activity against multiple cancer cell lines.
  • HY-116559
    TIBI
    		Inhibitor 99.62%
    TIBI is a potent and ATP-competitive inhibitor of Rio1 (IC50: 0.09 μM, Ki: 0.05 μM). TIBI enhances the thermostability of the enzyme Rio1.
  • HY-10424A
    Milciclib maleate
    		Inhibitor
    Milciclib (PHA-848125) maleate is a cyclin-dependent kinase inhibitor that impairs melanoma cell growth and modulates gene expression involved in cell cycle regulation. Milciclib maleate has been shown to significantly affect the expression of various genes, including down-regulating PTTG1, contributing to its antiproliferative activity. Milciclib maleate enhances sensitivity to treatment in p53 mutated melanoma cells when combined with PTTG1 silencing.
  • HY-156792
    RIOK2-IN-1
    		Inhibitor
    RIOK2-IN-1 (com 4) is a potent and selective RIOK2 inhibitor (Kd=150 nM), but has low cellular activity (IC50=14,600 nM). RIOK2 is an atypical kinase associated with a variety of human cancers and is involved in ribosome maturation and cell cycle progression. The small molecule inhibitor CQ211 (HY-147655), an improvement of RIOK2-IN-1 as the lead compound, has good in vivo and in vitro activity, inhibits the proliferation of MKN-1 and HT-29 cancer cells, and can xenograft MKN in mice -1 model inhibits tumor progression.
  • HY-156465
    RIOK2-IN-2
    		Inhibitor
    RIOK2-IN-2 (8) is a RIOK2 inhibitor, with IC50 values of 3.02 μM and 5.34 μM in MKN-1 and MOLT4 cells, respectively.